shift-study.com-shift / systolic heart failure treatment with the eml/emsubf/sub inhibitor ivabr

Données techniques du shift-study.com

Geo IP vous fournit comme la latitude, la longitude et l'ISP (Internet Service Provider) etc. informations. Notre service GeoIP a trouvé l'hôte shift-study.com.Actuellement, hébergé dans France et son fournisseur de services est OVH SAS .

Latitude:	50.69421005249
Longitude:	3.1745600700378
Pays:	France (fr)
Ville:	Roubaix
Région:	Nord-Pas-de-Calais
ISP:	OVH SAS

the related websites

domaine	Titre
shift-study.com	shift / systolic heart failure treatment with the eml/emsubf/sub inhibitor ivabr
heartfailurematters.org	heart failure matters
anuraga.org	anuraga publishing studio — from heart to heart
sai-acoustique.com	saifrance the science of silence, noise treatment, air treatment
wtt-francais.fr	wood and timber treatment plants \| wtt wood treatment technology
heartofglass-heartofgold.com	festival heart of glass, heart of gold – hog hog festival
failure-might.biz	failure-might.biz
freedomfromfailure.com	home - freedom from failure
autoecolefausten.com	domain name suspended due to registrant verification failure
sarebearsproducts.com	domain name suspended due to registrant verification failure
atelier-d-gillery.com	domain name suspended due to registrant verification failure
muzonvam.com	domain name suspended due to registrant verification failure
essentielcommunication.com	domain name suspended due to registrant verification failure
adep-roanne.org	domain name suspended due to registrant verification failure
stratus.com	stratus technologies \| we prevent applications from failure

Analyse d'en-tête HTTP

Les informations d'en-tête HTTP font partie du protocole HTTP que le navigateur d'un utilisateur envoie à appelé Apache contenant les détails de ce que le navigateur veut et acceptera de nouveau du serveur Web.

X-Powered-By:	PHP/7.1.17
Transfer-Encoding:	chunked
Set-Cookie:	SERVERID567=2040150; path=/; max-age=900
Content-Encoding:	gzip
Vary:	Accept-Encoding
Server:	Apache
Connection:	keep-alive
Link:	; rel="https://api.w.org/"
Date:	Thu, 19 Jul 2018 14:27:46 GMT
Content-Type:	text/html; charset=UTF-8

DNS

soa:	ns1.markmonitor.com. mail\.domaines.fr.netgrs.com. 2018042702 86400 3600 2592000 172800
ns:	ns5.markmonitor.com. ns7.markmonitor.com. ns3.markmonitor.com. ns4.markmonitor.com. ns2.markmonitor.com. ns6.markmonitor.com. ns1.markmonitor.com.
ipv4:	IP:46.105.57.169 ASN:16276 OWNER:OVH, FR Country:FR

HtmlToText

shift / systolic heart failure treatment with the <em>l</em><sub>f</sub> inhibitor ivabradine trial shift systolic heart failure treatment with the lf inhibitor ivabradine trial search for: skip to content home shift ivabradine heart rate & heart failure newsroom resources contact us shift in brief 6505 patients randomized 37 countries 677 centers overview -- study analyses heart rate & heart failure ivrabradine -- selective contemporary studies / registries in cad & hf -- news on shift new publication ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure a post-hoc analysis from shift assessed the impact of ivabradine on early readmissions in patients hospitalized for heart failure. ivabradine significantly reduced the risk of early recurrent hospitalizations following a first heart failure hospitalization. this reduction of risk was significant from the first month onwards (30% relative risk reduction, p<0.05), ranging from 21% to 30% within the first 3 months following a heart failure hospitalization. komajda m, tavazzi l, swedberg k, et al. chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of shift. eur j heart fail. 2016;18(9):1182-1189. this entry was posted in news on 10 march 2017 by lademine . ivabradine is effective in chronic heart failure patients whatever the number of comorbidities published in may 2015 an analysis from the shift trial assessed the impact of multiple comorbidities on outcomes and the potential impact on the benefits of ivabradine in heart failure patients. multimorbidity was associated with a higher risk of outcomes but, whatever the number of comorbidities, did not interfere with the effects of ivabradine in reducing the primary end point of cardiovascular death or hospitalization for heart failure or in reducing other heart failure-related outcomes. continue reading → this entry was posted in news on 30 june 2015 by lademine . shift is the basis for a prognostic model for heart failure patients published in april 2015 the shift prognostic model is based on simple clinical characteristics (increased resting hr, low ejection fraction, raised creatinine, new york heart association class iii/iv, longer duration of hf, history of left bundle branch block, low systolic blood pressure, age…) to provide prognostic information in patients with chronic heart failure, systolic dysfunction, and elevated hr 1 . continue reading → this entry was posted in news on 20 april 2015 by lademine . post navigation ← older posts this website is intended for an international audience. drug related information may refer to unlicensed products or uses which may not be approved in your own country and you should therefore consult your local prescribing information. this site is published and updated by the shift study investigators-©2018 shift. all rights reserved. report a side-effect with a drug. we use cookies to ensure that we give you the best experience on our website. if you continue to use this site we will assume that you are happy with it. ok read more

Analyse PopURL pour shift-study.com

https://www.shift-study.com/shift/
https://www.shift-study.com/new-modelshift-is-the-basis-for-a-prognostic-model-for-heart-failure-patients/#more-1452
https://www.shift-study.com/shift/shift-analyses/
https://www.shift-study.com/shift/shift-study/overview-of-shift/
https://www.shift-study.com/ivabradine-reduces-readmissions-in-the-vulnerable-phase-after-hospitalization-for-worsening-systolic-heart-failure/
https://www.shift-study.com/contact/
https://www.shift-study.com/page/2/
https://www.shift-study.com/newsroom/
https://www.shift-study.com/news-from-the-heart-failure-congress-2015-seville-may-2015ivabradine-is-effective-in-chronic-heart-failure-patients-whatever-the-number-of-comorbidities/
https://www.shift-study.com/resources/
https://www.shift-study.com/new-modelshift-is-the-basis-for-a-prognostic-model-for-heart-failure-patients/
https://www.shift-study.com/ivrabradine/
https://www.shift-study.com/news-from-the-heart-failure-congress-2015-seville-may-2015ivabradine-is-effective-in-chronic-heart-failure-patients-whatever-the-number-of-comorbidities/#more-1480
https://www.shift-study.com/#content
https://www.shift-study.com/heart-rate-heart-failure/

Informations Whois

Whois est un protocole qui permet d'accéder aux informations d'enregistrement.Vous pouvez atteindre quand le site Web a été enregistré, quand il va expirer, quelles sont les coordonnées du site avec les informations suivantes. En un mot, il comprend ces informations;

Domain Name: shift-study.com
Registry Domain ID: 358766966_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.markmonitor.com
Registrar URL: http://www.markmonitor.com
Updated Date: 2016-12-01T04:00:21-0800
Creation Date: 2006-02-27T00:00:00-0800
Registrar Registration Expiration Date: 2018-02-27T00:00:00-0800
Registrar: MarkMonitor, Inc.
Registrar IANA ID: 292
Registrar Abuse Contact Email: abusecomplaints@markmonitor.com
Registrar Abuse Contact Phone: +1.2083895740
Domain Status: clientUpdateProhibited (https://www.icann.org/epp#clientUpdateProhibited)
Domain Status: clientTransferProhibited (https://www.icann.org/epp#clientTransferProhibited)
Domain Status: clientDeleteProhibited (https://www.icann.org/epp#clientDeleteProhibited)
Registry Registrant ID:
Registrant Name: Domain Manager
Registrant Organization: BIOFARMA
Registrant Street: 50 rue Carnot,
Registrant City: SURESNES
Registrant State/Province: cedex
Registrant Postal Code: 92284
Registrant Country: FR
Registrant Phone: +33.155726000
Registrant Phone Ext:
Registrant Fax: +33.155725269
Registrant Fax Ext:
Registrant Email: mail.domaines@servier.com
Registry Admin ID:
Admin Name: Domain Manager
Admin Organization: BIOFARMA
Admin Street: 50 rue Carnot,
Admin City: SURESNES
Admin State/Province: cedex
Admin Postal Code: 92284
Admin Country: FR
Admin Phone: +33.155726000
Admin Phone Ext:
Admin Fax: +33.155725269
Admin Fax Ext:
Admin Email: mail.domaines@servier.com
Registry Tech ID:
Tech Name: Domain Technical
Tech Organization: MarkMonitor Inc.
Tech Street: 3540 East Longwing Lane, Suite 300
Tech City: Meridian
Tech State/Province: ID
Tech Postal Code: 83646
Tech Country: US
Tech Phone: +1.2083895740
Tech Phone Ext:
Tech Fax: +1.2083895771
Tech Fax Ext:
Tech Email: ccops@markmonitor.com
Name Server: ns5.markmonitor.com
Name Server: ns4.markmonitor.com
Name Server: ns1.markmonitor.com
Name Server: ns2.markmonitor.com
Name Server: ns6.markmonitor.com
Name Server: ns3.markmonitor.com
Name Server: ns7.markmonitor.com
DNSSEC: unsigned
URL of the ICANN WHOIS Data Problem Reporting System: http://wdprs.internic.net/
>>> Last update of WHOIS database: 2017-07-25T02:54:01-0700 <<<

The Data in MarkMonitor.com's WHOIS database is provided by MarkMonitor.com for
information purposes, and to assist persons in obtaining information about or
related to a domain name registration record. MarkMonitor.com does not guarantee
its accuracy. By submitting a WHOIS query, you agree that you will use this Data
only for lawful purposes and that, under no circumstances will you use this Data to:
(1) allow, enable, or otherwise support the transmission of mass unsolicited,
commercial advertising or solicitations via e-mail (spam); or
(2) enable high volume, automated, electronic processes that apply to
MarkMonitor.com (or its systems).
MarkMonitor.com reserves the right to modify these terms at any time.
By submitting this query, you agree to abide by this policy.

MarkMonitor is the Global Leader in Online Brand Protection.

MarkMonitor Domain Management(TM)
MarkMonitor Brand Protection(TM)
MarkMonitor AntiPiracy(TM)
MarkMonitor AntiFraud(TM)
Professional and Managed Services

Visit MarkMonitor at http://www.markmonitor.com
Contact us at +1.8007459229
In Europe, at +44.02032062220

For more information on Whois status codes, please visit
https://www.icann.org/resources/pages/epp-status-codes-2014-06-16-en

  REGISTRAR MARKMONITOR INC.

  REFERRER http://www.markmonitor.com

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =shift-study.com

  PORT 43

  SERVER whois.markmonitor.com

  ARGS shift-study.com

  PORT 43

  TYPE domain
RegrInfo
DOMAIN

  NAME shift-study.com

NSERVER

  NS1.MARKMONITOR.COM 64.124.69.50

  NS2.MARKMONITOR.COM 162.88.60.13

  NS3.MARKMONITOR.COM 162.88.61.15

  NS4.MARKMONITOR.COM 162.88.60.15

  NS5.MARKMONITOR.COM 162.88.61.17

  NS6.MARKMONITOR.COM 162.88.60.17

  NS7.MARKMONITOR.COM 162.88.61.19

STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited

  CHANGED 2016-01-26

  CREATED 2006-02-27

  EXPIRES 2018-02-27

  REGISTERED yes

Go to top

shift-study.com rapport : Visitez le site